1887

Abstract

Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant (MRSA). Our case is unique in the description of an MRSA USA 300 isolate that developed decreased susceptibility to daptomycin during daptomycin and vancomycin therapy. Directed sequencing detected a previously reported mutation in , resulting in a T345A substitution, associated with non-susceptibility to daptomycin.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.2008/000588-0
2008-08-01
2020-05-27
Loading full text...

Full text loading...

/deliver/fulltext/jmm/57/8/1036.html?itemId=/content/journal/jmm/10.1099/jmm.0.2008/000588-0&mimeType=html&fmt=ahah

References

  1. Alborn W. E., Allen N. E., Preston D. A. 1991; Daptomycin disrupts membrane potential in growing Staphylococcus aureus . Antimicrob Agents Chemother 35:2282–2287 [CrossRef]
    [Google Scholar]
  2. Bannerman T. L., Hancock G. A., Tenover F. C., Miller J. M. 1995; Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus . J Clin Microbiol 33:551–555
    [Google Scholar]
  3. CLSI 2007 Performance Standards for Antimicrobial Susceptibility Testing . Approved Standards M100-S17 Wayne, PA: Clinical and Laboratory Standards Institute;
    [Google Scholar]
  4. Cui L., Tominaga E., Neoh H., Hiramatsu K. 2006; Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin intermediate Staphylococcus aureus . Antimicrob Agents Chemother 50:1079–1082 [CrossRef]
    [Google Scholar]
  5. Diep B. A., Gill S. R., Chang R. F., Phan T. H., Chen J. H., Davidson M. G., Lin F., Lin J., Carleton H. A. other authors 2006; Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus . Lancet 367:731–739 [CrossRef]
    [Google Scholar]
  6. Eisenstein B. I. 2004; Lipopeptides, focusing on daptomycin for the treatment of gram-positive infections. Expert Opin Investig Drugs 13:1159–1169 [CrossRef]
    [Google Scholar]
  7. Fey P. D., Said-Salim B., Rupp M. E., Hinrichs S. H., Boxrud D. J., Davis C. C., Kreiswirth B. N., Schlievert P. M. 2003; Comparative molecular analysis of community or hospital-acquired methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother 47:196–203 [CrossRef]
    [Google Scholar]
  8. Friedman L., Alder J. D., Silverman J. A. 2006; Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus . Antimicrob Agents Chemother 50:2137–2145 [CrossRef]
    [Google Scholar]
  9. Jones T., Yeaman M. R., Sakoulas G., Yang S. J., Proctor R. A., Sahl H. G., Schrenzel J., Xiong Y. Q., Bayer A. S. 2008; Failures in clinical treatment of Staphylococcus aureus with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52:269–278 [CrossRef]
    [Google Scholar]
  10. Kaatz G. W., Lundstrom T. S., Seo S. M. 2006; Mechanisms of daptomycin resistance in Staphylococcus aureus . Int J Antimicrob Agents 28:280–287 [CrossRef]
    [Google Scholar]
  11. Mangili A., Bica I., Snydman R., Hamer D. H. 2005; Daptomycin-resistant methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40:1058–1060 [CrossRef]
    [Google Scholar]
  12. Marty F. M., Yeh W. W., Wennersten C. B., Venkataraman L., Albano E., Alyea E. P., Gold H. S., Baden L. R., Pillai S. K. 2006; Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 44:595–597 [CrossRef]
    [Google Scholar]
  13. McDougal L. K., Steward C. D., Killgore G. E., Chaitram J. M., McAllister S. K., Tenover F. C. 2003; Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 41:5113–5120 [CrossRef]
    [Google Scholar]
  14. Naimi T. S., LeDell K. H., Como-Sabetti K., Borchardt S. M., Boxrud D. J., Etienne J., Johnson S. K., Vandenesch F., Fridkin S. other authors 2003; Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976–2984 [CrossRef]
    [Google Scholar]
  15. Sakoulas G., Alder J., Thauvin C., Moellering R. C., Eliopolous G. M. 2006; Induction of daptomycin heterogenous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50:1581–1585 [CrossRef]
    [Google Scholar]
  16. Silverman J. A., Perlmutter N. G., Shapiro H. M. 2003; Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus . Antimicrob Agents Chemother 47:2538–2544 [CrossRef]
    [Google Scholar]
  17. Skiest D. J. 2006; Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44:655–656 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.2008/000588-0
Loading

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error